



## Galecto to Participate in Jefferies London Healthcare Conference

November 3, 2022

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming Jefferies London Healthcare Conference taking place on November 15-17, 2022. Details for the event are as follows:

### Jefferies London Healthcare Conference

*Date:* Wednesday, November 16, 2022  
*Time:* 7:25 am GMT  
*Webcast:* [Click Here](#)

A live webcast of the presentation will be available on the "News & Events" section of Galecto's Investor website at <https://ir.galecto.com/news-and-events/events>. A replay of the presentation will be available on this same website following the event.

### About Galecto

Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate Phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit [www.galecto.com](http://www.galecto.com).

### For more information, contact:

#### Galecto, Inc.

Hans Schambye, CEO  
Jon Freve, CFO  
+45 70 70 52 10

#### Investors/US

Ashley R. Robinson  
[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)  
+1 617 430 7577

#### Media/EU

Sandya von der Weid  
[svonderweid@lifesciadvisors.com](mailto:svonderweid@lifesciadvisors.com)  
+41 78 680 0538



Source: Galecto, Inc.